Benefits
IMPORTANT: prescription drug, not a supplement
Mildronate (meldonium) is a prescription cardiac drug approved only in Latvia, Russia and other ex-Soviet/CIS countries. It is NOT an FDA- or EMA-approved drug and is NOT a dietary supplement. The uses listed below are foreign medical indications for a prescribed drug, not supplement benefits you should seek on your own. Meldonium has been on the WADA Prohibited List since 1 January 2016. Do not self-administer; use only under qualified medical supervision.
Post-myocardial infarction heart failure
In the early post-MI period, small Russian studies added mildronate to standard therapy. The 2015 randomized study (n=67) gave oral mildronate for 12 weeks and reported fewer angina attacks, fewer arrhythmias, lower blood pressure and improved quality of life; no hard heart-failure or mortality endpoints were measured. This is a foreign medical indication supported only by small single-country trials.
Peripheral arterial disease / claudication
Peripheral arterial disease / claudication is listed as an approved indication in some ex-Soviet/CIS countries. No citable Western RCT confirming a claudication exercise-tolerance benefit could be verified; treat any specific efficacy figures as unestablished.
Stable angina (MILSS I multinational RCT plus Russian studies)
Multiple smaller Russian RCTs report benefit in stable angina pectoris. Honest framing: nearly all published clinical efficacy studies on meldonium are in Russian — a substantial methodological access limitation for Western evidence assessment.
Cerebral ischemia / acute stroke (Phase II)
A Phase II acute ischemic stroke trial (Zhu 2013) compared mildronate against an active drug with no placebo arm and was not superior on its primary disability endpoint. Cerebrovascular disease is an approved indication in some CIS countries, but this trial did not show mildronate outperforms the comparator.
Diabetic neuropathy adjunct
Listed as an approved indication in some CIS countries for diabetic peripheral neuropathy, based on presumed cardiovascular/microcirculatory effects. This is a foreign regulatory indication and is not established by any trial cited on this page.
WADA prohibition + Sharapova case (regulatory context)
Added to WADA Prohibited List January 1, 2016 based on cited 'potential performance enhancement' — a controversial decision. March 2016: Maria Sharapova publicly admitted use, lost 2016 Australian Open results, received 15-month suspension — the most prominent meldonium WADA case. Other athletes also tested positive (Pavel Kulizhnikov, Eduard Vorganov, Ukrainian biathletes). April 2016 WADA u-turn admitted uncertainty about meldonium body persistence; many low-concentration positives reflected pre-ban use, and most cases were dropped except Sharapova's (high concentration confirmed continued use).
Mechanism of action
γ-butyrobetaine hydroxylase inhibition (carnitine biosynthesis blocker)
Meldonium (3-(2,2,2-trimethylhydrazine)propionate dihydrate; CAS 76144-81-5) is a competitive inhibitor of γ-butyrobetaine hydroxylase — the enzyme that converts γ-butyrobetaine to L-carnitine. The inhibition reduces carnitine biosynthesis, which in turn reduces fatty acid mitochondrial transport. Mechanistically distinct from cardioactive drugs that act on adrenergic, calcium-channel, or RAAS pathways.
Cardiac metabolism shift: fatty acid → glucose oxidation
Reduced fatty acid mitochondrial transport shifts cardiac energy metabolism from fatty acid oxidation (oxygen-intensive) to glucose oxidation (more oxygen-efficient — produces more ATP per unit oxygen consumed). Restores energy production efficiency under ischemic or hypoxic conditions where oxygen supply is limited. The proposed cardiac protection mechanism.
Increased glucose uptake
Downstream effect of the metabolism shift — increased glucose uptake into cardiomyocytes supports the glucose-oxidation pathway and improves substrate utilization during ischemic stress.
Endothelial function improvement
Endothelial NO production improvement contributes to the cardiovascular and microcirculatory benefits — relevant to PAD, diabetic neuropathy, and cerebrovascular indications.
Peroxisome activity increase
Increased peroxisome activity contributes to fatty acid metabolism redirection — peroxisomes handle very-long-chain fatty acid oxidation, providing alternative metabolic capacity beyond mitochondrial fatty acid β-oxidation.
Neuroprotective effects in cerebral ischemia
The same metabolic shift mechanisms that protect cardiomyocytes during ischemia apply to neurons during cerebral ischemia — underlying the cerebrovascular and stroke indications.
Clinical trials
Clinical studies of meldonium as an adjunct in post-myocardial infarction patients (Nechaeva 2014, PMID 25702409; Nechaeva 2015, PMID 26761970).
Post-MI patients (Nechaeva 2014/2015)
Small Russian post-MI studies (Nechaeva 2014, PMID 25702409; Nechaeva 2015, PMID 26761970). The 2015 randomized study (n=67) added oral mildronate for 12 weeks to standard therapy and reported fewer angina attacks, fewer arrhythmias, lower blood pressure and better quality of life. No hard heart-failure or mortality endpoints were measured, and both are single-country, Russian-language sources.
Added to WADA Prohibited List January 1, 2016.: Maria Sharapova admitted use, 15-month suspension.
Regulatory/anti-doping context — not a clinical trial.
Added to WADA Prohibited List January 1, 2016.: Maria Sharapova admitted use, 15-month suspension. WADA u-turn admitted uncertainty about body persistence — many low-concentration positives reflected pre-ban use; most cases dropped except Sharapova's. Reflects regulatory ambiguity rather than a clear-cut performance-enhancement determination.